Mabwell-b
2493.HK
Hong Kong Stock Exchange26.00
HKD
-0.40
- -
ISIN
CNE100007HT5
Return %
Stock
S&P500
1Y
-2.18
22.23
3Y
-2.18
69.34
5Y
-2.18
73.59
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Datao Liu
- Full Time Employees
- 1,325
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 2 Shanghai SH People's Republic of China 201210
- IPO Date
- May 12, 2026
- Website
- mabwell.com
- Similar Companies
- Business
- Mabwell-B is an innovative biopharmaceutical company focused on the research, development, manufacturing and commercialization of novel cancer, immune, ocular and orthopedic therapies, with an integrated industry chain from discovery to market. It operates across the full value chain including discovery, preclinical and clinical development, process development, scale-up, GMP-compliant manufacturing, regulatory submissions and global commercialization, aiming to deliver differentiated biologics, antibody-drug conjugates (ADCs), recombinant proteins and small-molecule therapeutics to address unmet medical needs. The company maintains a broad portfolio centered on targeted oncology and immunology programs, including Nectin-4 targeting ADCs and other novel constructs, with strategic emphasis on advancing clinical programs through Phase I–III trials and pursuing international collaborations to expand global patient access. Geographic footprint and operations span China with a focus on internal研发 capabilities and manufacturing, and selected international partnerships to support clinical development, regulatory submissions and co-development opportunities. Mabwell-B was founded in the 2010s and is headquartered in Shanghai, China, with ongoing initiatives to extend its geographic reach through partnerships and potential global manufacturing collaborations. The organization emphasizes an end-to-end approach, leveraging in-house biologics discovery platforms, translational science, and contract manufacturing capabilities to accelerate development timelines and ensure supply continuity for pipeline products and clinical trial materials. The company also maintains regulatory and quality systems to support global trials and potential commercialization across multiple regions. Latest major company changes include: formation of strategic alliances and partnerships to advance pipeline programs and expand clinical development across multiple jurisdictions; continued progression of lead ADC programs with regulatory submissions and IND/clinical trial approvals in various markets; launches of new program updates and expansions in immuno-oncology and targeted therapy indications; organizational refinements and potential leadership or structural realignments to support accelerated growth; and enhancements to manufacturing capacity and supply chain resilience to support broader clinical and early commercial activities. Industry context and business segments: biopharmaceutical research and development; biologics discovery and development; ADCs and targeted therapies; recombinant proteins and small-molecule drugs; contract development and manufacturing services; global clinical development support and regulatory affairs. Target customers include pharmaceutical and biotech partners, contract research and manufacturing organizations, academic clinical researchers, and healthcare providers seeking innovative therapies. Substantial subsidiary activity and potential parent-subsidiary relationships underpin the group structure, with Mabwell-B positioning itself as a vertically integrated innovator capable of delivering next-generation therapeutic modalities.